Sermorelin vs Tesamorelin: How These Two GHRH Peptides Compare

Sermorelin and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs that tell the pituitary to release growth hormone, but they are not interchangeable. Tesamorelin is FDA-approved for one specific medical condition, reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, while sermorelin is a shorter-acting, older peptide that no longer has an FDA-approved brand in the United States. Which one is better depends on the goal, the prescription, and how much clinical evidence sits behind each option.

What Is Sermorelin?

Sermorelin is a 29-amino-acid fragment of GHRH, sometimes called GRF 1-29. It was previously FDA-approved as Geref for evaluating and treating growth hormone deficiency in children, but that brand was discontinued in the U.S. in 2008. Today sermorelin is sold mainly through compounding pharmacies with a prescription, or as a research chemical labeled not for human use.

• Half-life: roughly 10 to 20 minutes
• Typical dosing: 100 to 300 mcg injected subcutaneously at night
• FDA status: no current approved brand in the U.S.
• Common reputation: a milder, lower-cost GHRH option

Sermorelin breaks down quickly, which is why most protocols call for nightly injections. Many people searching sermorelin vs tesamorelin are really asking whether a cheaper, gentler peptide can do the same job as a prescription drug.

What Is Tesamorelin?

Tesamorelin is a 44-amino-acid GHRH analog sold under the brand names Egrifta SV and Egrifta WR. It is FDA-approved to reduce excess visceral abdominal fat in adults living with HIV and lipodystrophy. Tesamorelin resists enzyme breakdown better than sermorelin, so it stays active longer and produces a stronger, more sustained growth hormone pulse.

• Half-life: roughly 26 to 38 minutes
• Approved dose: 1.4 mg (Egrifta SV) or 2 mg (Egrifta WR) injected subcutaneously once daily
• FDA status: approved for HIV-associated visceral adiposity only
• Evidence: multiple randomized trials showing visceral fat reduction

Tesamorelin is not approved for general weight loss, bodybuilding, or anti-aging. Those uses are off-label at best and unsupported by controlled data.

Sermorelin vs Tesamorelin at a Glance

Factor	Sermorelin	Tesamorelin
Amino acids	29	44
Half-life	About 10 to 20 minutes	About 26 to 38 minutes
FDA approval	None currently (Geref discontinued in 2008)	Approved for HIV-associated lipodystrophy
Typical dose	100 to 300 mcg nightly	1.4 to 2 mg once daily
Best-studied effect	Stimulating GH and IGF-1	Reducing visceral fat
Bodybuilding evidence	Weak and anecdotal	Weak and indirect

FDA Status and Approved Uses

The approval gap is the single biggest practical difference between these two peptides. Tesamorelin holds an FDA approval with a defined indication, a defined dose, and required monitoring. Sermorelin does not.

That distinction matters for three reasons:

1. Legal access. A clinician can prescribe tesamorelin for its approved indication. Compounded sermorelin sits in a grayer regulatory area.
2. Insurance. Tesamorelin may be covered for HIV-associated lipodystrophy. Sermorelin almost never is.
3. Quality control. Approved drugs come with batch testing and sterility standards. Research-grade peptides sold online often do not.

People searching tesamorelin vs sermorelin which is better often skip the step that matters most: deciding whether a prescription is appropriate in the first place.

Bodybuilding, Fat Loss, and Realistic Expectations

Neither peptide builds muscle the way anabolic steroids do. Both raise growth hormone and IGF-1 modestly, which may shift body composition over months but will not produce dramatic size gains on its own.

In the tesamorelin vs sermorelin for bodybuilding debate, the honest answer is that tesamorelin has the better fat-loss data and sermorelin has the better price. Tesamorelin's trials measured visceral fat, the deep fat around the organs, not the subcutaneous fat most people are trying to lose.

Suppliers often market these peptides as fat burners, and that framing oversells them. If you are comparing compounds, it helps to read broader head-to-heads such as tesamorelin vs sermorelin vs cjc-1295 and sermorelin vs aod 9604 before picking one.

Dosing, Timing, and Bloodwork

Sermorelin is usually injected at night to mimic the body's natural overnight growth hormone pulse, while tesamorelin is dosed once daily, often in the evening. Neither should be started without baseline labs.

Because both compounds raise IGF-1, monitoring matters. A clinician will typically check IGF-1 levels, fasting glucose, and A1c before and during treatment, and will reassess if side effects appear.

If you are mapping out injectable schedules, comparisons such as cjc 1295 no dac vs sermorelin are useful because they focus on half-life and pulse shape rather than marketing language.

Side Effects and Safety

• Injection site reactions such as redness, pain, or lumps
• Joint aches and stiffness
• Fluid retention and swelling
• Carpal tunnel-like numbness or tingling
• Headache and irritability
• Elevated IGF-1, a theoretical concern for tumor growth
• Changes in blood sugar, especially in people with diabetes

Tesamorelin's label carries warnings about increased IGF-1, fluid retention, and glucose intolerance. Sermorelin has less formal safety data because no current approved label exists for it.

Neither peptide has been shown to be safe or effective for general weight loss or athletic performance in healthy adults.

What Reddit Threads Get Right and Wrong

Search tesamorelin vs sermorelin reddit and you will find a mix of detailed personal logs and confident claims backed by very little. A few patterns do hold up.

• Users consistently report injection site reactions with both compounds.
• Cost complaints are far more common with tesamorelin.
• Fat-loss results are inconsistent, which matches the clinical data.

What does not hold up: dosing advice from strangers, claims that these peptides are harmless because the body already makes growth hormone, and vendor recommendations from accounts with no bloodwork to show. Reddit is useful for spotting side effects to watch for, but it is not a substitute for medical supervision.

Cost and Access

Tesamorelin is expensive and can run well over a thousand dollars per month without insurance. Compounded sermorelin costs less, but it still requires a prescription from a licensed clinician, and the compounded market is lightly regulated.

Peptides sold as research chemicals are not tested for purity or sterility, and injecting them carries real risk of contamination and dosing errors. A related option some people compare is igf-1 lr3 vs sermorelin, though IGF-1 LR3 acts downstream of the pituitary and carries its own risks, including hypoglycemia.

Bottom Line

If you have HIV-associated lipodystrophy and qualify for treatment, tesamorelin is the evidence-backed choice. Everyone else is comparing an off-label prescription drug to a peptide with no current FDA approval, and neither is a shortcut to a lean physique.

Talk with a licensed healthcare professional before starting either compound, and ask about baseline and follow-up bloodwork if one is prescribed.

RELATED PEPTIDE TOPICTesamorelin peptide research

COMMON QUESTIONS

Frequently Asked Questions

Which is better, sermorelin or tesamorelin?

It depends on the goal. Tesamorelin has the stronger clinical evidence because it is FDA-approved for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin costs less and is often used off-label for general wellness, but it has no current FDA-approved brand in the U.S. and much weaker supporting data.

Are sermorelin and tesamorelin FDA-approved?

Tesamorelin is FDA-approved under the brand names Egrifta SV and Egrifta WR for excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin was previously approved as Geref, but that product was discontinued in the U.S. in 2008, so no sermorelin brand is currently approved. Compounded versions of either peptide are not FDA-approved products.

Can you take sermorelin and tesamorelin together?

There is no published clinical research supporting a stack of two GHRH analogs. Both act on the same pituitary receptor, so combining them is unlikely to add benefit and may simply raise IGF-1 and side effect risk further. If you are considering either peptide, discuss it with a healthcare professional rather than stacking them on your own.